research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-12. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of S. hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the US Food and Drug Administration (FDA) in 1999. Hyftor (sirolimus gel) was authorized for topical treatment of facial angiofibroma in the European Union in May 2023.
The Defense Secretary threatened Anthropic, the owner of Claude AI (the only AI authorized by the Department of Defense in early 2026), to designate the company a supply chain risk and force the company to eliminate its restrictions on the use of its AI by the Defense Department or he will use the Defense Production Act to compel them. The Defense Department gave Anthropic a deadline of February 27, 2026. The contract Sec. Hegseth wanted to cancel was worth $200 million. A senior defense official stated that the company will "pay a price for forcing our hand like this." Anthropic stated that they wanted assurances that the DoD would not use their AI tools to spy on Americans or develop weapons that could fire without human involvement. The Defense Department also stated in February 2026 that Grok, OpenAI and Google were close to being approved for use. Claude was used by the Pentagon during their January 2026 operation to capture Nicolas Maduro. In May 2026, the Defense Department announced AI use deals with SpaceX, OpenAI, Google, NVIDIA, Reflection, Microsoft and Amazon Web Services. On February 27, 2026, Hegseth used the Federal Acquisition Supply Chain Security Act to declare Anthropic a supply chain risk and excluded it from all federal contracts. President Trump also stated that every federal agency must stop using Anthropic's AI technology. ChatGPT signed a deal with the Defense Department the same day but their CEO Sam Altman said, "the AI system shall not be intentionally used for domestic surveillance of U.S.
=== Outreach === Nigam is a trained STEM Ambassador and delivers lessons on microbiology and entomology to pupils at local schools. She participated in the 2014 Soapbox Science public engagement event in Swansea. Nigam works to change the Welsh school curriculum in order to promote gender equality in STEM.
Sources: en.wikipedia.org
Biological and biotechnical rejuvenation-related results A new cellular rejuvenation therapy of bursts of iPSC reprogramming is reported, which can reverse aspects of aging in mice, without causing cancer or other health problems. Bioresearchers demonstrate an in vitro method (MPTR) for rejuvenation (including the transcriptome and epigenome) reprogramming, working better than previous reprogramming methods, in which fibroblast skin cells temporarily lose their cell identity. Scientists report the key molecular mechanisms of rejuvenation they found in a comparison of the newly presented genomes of the biologically immortal T. dohrnii and a similar but non-rejuvenating jellyfish, involving e.g. DNA replication and repair, and stem cell renewal. A first spatiotemporal map reveals key insights about axolotl brain regeneration. Axolotls retain regenerative capacity in their aging throughout their lives. It is thought that by "understanding the mechanisms of regeneration, we eventually will be able to enhance our intrinsic regenerative abilities in order to slow and even reverse the damage of aging." Scientists report leprosy-causing bacteria viably regenerate and rejuvenate the liver in its armadillos hosts, which may enable novel human therapies. A study shows that infusing the nourishing cerebrospinal fluid from around brain cells of young mice into aged brains rejuvenates aspects of the brain, identifying FGF17 as a key target for potential therapeutics such as of anti-aging.
=== Daria Greenock === Daria Greenock (Freya Mavor) is a VP at Pierpoint's CPS desk, and Harper's line manager during her internship. Daria works to foster a poised, professional relationship with Harper, who nonetheless finds herself drawn more to Eric's fiery, cutthroat management style, frequently undercutting Daria in the process. When Harper confides to Daria that Eric locked her in a conference room to berate her for a mistake, Daria tells Sara and the two push Harper to file a formal complaint, getting Eric fired and positioning Daria to become CPS' managing director in his place. Harper is initially allowed to keep the outsize bonus that Eric paid her as long as she keeps it quiet, but Daria later has Harper pay it back after Harper talks about it during a party. On RIF day, Harper accepts a deal to retract her complaint against Eric and get him rehired, leading to Daria's firing. In series 2, Daria is revealed to have joined Goldman Sachs; though she is on maternity leave, she visits the office during a sham interview with Harper, Eric, and Rishi to revel in their humiliation. In series 3, however, Daria agrees to help Harper short Pierpoint alongside Kenny and Jackie, who have also joined Goldman Sachs, out of spite towards their ex-employer.
==== Territorial Control Plan ==== On 19 June 2019, Bukele announced that his government would implement a seven-phase security Territorial Control Plan that sought to disrupt gang finances. The plan began that night at midnight. Phase one, known as "preparation", called for members of the country's security forces — the Armed Forces of El Salvador and the National Civil Police (PNC) — to be stationed in 12 of the country's 262 municipalities at locations where gangs were known to collect renta. The government also implemented a temporary state of emergency in El Salvador's 28 prisons, putting them on lockdown and banning visitors.
== Sequels == Half-Life 2: Episode Two was released in 2007. Episode Three was scheduled for release by Christmas 2007, but was canceled as Valve found the episodic model contrary to their growing ambition for new installments, and needed to dedicate resources to Left 4 Dead, which was nearing completion. After canceling several further Half-Life projects, Valve released a prequel, Half-Life: Alyx, in 2020.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.